ACELYRIN INC (SLRN) Stock Price, Quote, News and Summary
NASDAQ:SLRN - Nasdaq - US00445A1007 - Common Stock
SLRN Quote and Key Statistics
ACELYRIN INC
NASDAQ:SLRN (1/17/2025, 8:27:34 PM)
After market: 2.02 +0.03 (+1.51%)1.99
0 (0%)
SLRN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.76% | ||
| ROE | -50.05% | ||
| Debt/Equity | 0 |
SLRN Performance and Technical Analysis
SLRN Ownership and Analysts
SLRN Latest News and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Tuesday's session: gap up and gap down stocks
Gap analysis on 2025-01-07: gap up and gap down stocks in today's session.
Curious about the stocks that are showing activity before the opening bell on Tuesday?
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
About SLRN
Company Profile
ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 130 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Company Info
ACELYRIN INC
4149 Liberty Canyon Road
Agoura Hills CALIFORNIA US
Employees: 93
Company Website: https://www.acelyrin.com/
Investor Relations: https://acelyrin.com/for-investors
Phone: 18057300360
SLRN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |